2N Pharma is developing therapeutics for the treatment of ALS, Parkinson’s and other neurodegenerative diseases. Based on research by co-founder and CSO, Dr. John Nieland and his team at Aalborg University, Denmark, 2N Pharma has developed novel, orally administered, small molecule therapeutic drug candidates that cross the blood-brain barrier to target mitochondrial dysfunction that has been linked to disease progression in several neurodegenerative diseases. We believe our approach will herald a paradigm shift in the fundamental understanding of the etiology and development of neurodegeneration.
